Hydroxycarbamide (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.
EML status history
Therapeutic equivalent for
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Other medicines for haemoglobinopathies
- Oral > Solid: 200 mg; 500 mg; 1 g